News
Latest News
Stay updated with GRP Japan
News by Topic
Filter the latest news by choosing categories below.
Global Regulatory Partners Announces MHLW Approval of Pegfilgrastim Biosimilar in Japan
Tokyo, Japan – August 25, 2026 – Global Regulatory Partners GK (GRP GK) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) granted marketing approval on August 24, 2026, for Pegfilgrastim BS Subcutaneous Injection 3.6 mg 「GRP」, a pegfilgrastim biosimilar indicated for the prevention of febrile neutropenia associated with cancer chemotherapy.Global Regulatory Partners GK Joins the Japan Diabetes Society as a Supporting Member
Global Regulatory Partners GK has been officially accepted as a Supporting Member of the Japan Diabetes Society (JDS).GRP Officially Becomes a Member of Japan Association for Diabetes Education and Care (JADEC)
This membership underscores GRP’s commitment to expanding access to educational resources for patients, schools, and institutions, while promoting awareness and preparedness for hypoglycemic emergencies across Japan.
